Ero sivun ”Rituksimabi” versioiden välillä

18 merkkiä poistettu ,  10 vuotta sitten
[katsottu versio][katsottu versio]
Rituksiimabin kehitti [[Biogen Idec|IDEC Pharmaceuticals]] tuotenimellä '''IDEC-C2B8'''.<ref>[ "Why San Diego Has Biotech"], Fikes, Bradley J. ''San Diego Metropolitan,'' April 1999. Accessed June 20, 2008.</ref>
BasedPerustuen on[[Kliininen itstutkimus| safetykliinisiin and effectiveness in [[clinical trialtutkimuksiin]]s,<ref>{{cite journal |author=Maloney DG, Grillo-López AJ, White CA, ''et al.'' |title=IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma |journal=Blood |volume=90 |issue=6 |pages=2188–95 |year=1997 |month=September |pmid=9310469 |doi= |url=}}</ref> rituximabrituksiimabi wassai approvedhyväksynnän by theUSA:n [[U.S. Food and Drug AdministrationFDA]]:lta invuonna 1997 to treat B-cell [[non-Hodgkin lymphoma]]s resistant to other [[chemotherapy]] regimens.<ref>{{cite journal |author=Scott SD |title=Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma |journal=Cancer Pract |volume=6 |issue=3 |pages=195–7 |year=1998 |pmid=9652253 |doi= 10.1046/j.1523-5394.1998.006003195.x|url=}}</ref> Rituximab, in combination with [[CHOP]] chemotherapy, is superior to CHOP alone in the treatment of [[diffuse large B-cell lymphoma]] and many other B-cell lymphomas.<ref>''Harrison's Principles of Internal Medicine'', Longo et al. ''McGraw Hill Medical'' 2011 page 931</ref> In 2010 it was approved by the [[European Commission]] for maintenance treatment after initial treatment of [[follicular lymphoma]].<ref>{{cite news |url= |title=Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy |date=October 29, 2010 }}</ref>
Rituximab is currently co-marketed by [[Biogen Idec]] and [[Genentech]] in the U.S., by [[Hoffmann–La Roche]] in Canada and the [[European Union]], and by [[Chugai Pharmaceuticals]] and Zenyaku Kogyo in Japan.
1 204